Please assess the completion status of the following clinical trial:

Trial Title: Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and over~* Type 1 diabetes on MDI with bolus injections for \>6 months prior to study enrolment or Type 2 diabetes treated with 2 or more insulin injections daily.~* In the investigator's opinion, thought technically capable of using FreeStyle Navigator GM System device.~* HbA1c between 7.5 and 12.0% (58 to 108 mmol/mol) for previous test obtained within 6 months prior to point of enrolment~Exclusion Criteria:~* Concomitant disease or condition that may compromise patient safety, including unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or any uncontrolled chronic medical condition~* Female subject is pregnant or planning to become pregnant within the planned study duration. Subjects who become pregnant during the study will be discontinued from the study.~* Currently using / has previously used a Continuous Glucose Monitoring System within the last 6 months.~* Currently using Continuous Subcutaneous Insulin Infusion (CSII)~* Currently using basal/long acting insulin only.~* Participating in another study of a glucose monitoring device / drug that could affect glucose measurements / management~* Known allergy to medical grade adhesives~* In the investigators opinion is unsuitable to participate due to any other cause/reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CGM - intervention arm (Type: EXPERIMENTAL): Following a 14 day masked (baseline) period using the FreeStyle Navigator subjects will wear an unmasked FreeStyle Navigator with the glucose alarms switched off.
- SMBG - Control arm (Type: ACTIVE_COMPARATOR): Following a 14 day masked ( baseline) period using the FreeStyle Navigator subjects will manage their blood glucose with a standard SMBG and use a FreeStyle Navigator masked for a 14 day period at the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).